Follow Us: Follow Prostate on Facebook Follow ProstateNet on Twitter Get the Prostate.net RSS feed

Category Archives: Urinary Incontinence

  • Related Categories
    • No categories

Is Incontinence/Overactive Bladder Over-Treated?

Two Finnish experts have questioned the idea of the ‘overactive bladder syndrome’. According to them, this syndrome is mostly beneficial to those with commercial interests, while from the patient perspective and for the development of treatments, it may be detrimental. “The overactive bladder syndrome has become an accepted way to simplify a complex array of… Continue Reading »


More about:

FDA OKs Antares Pharma Overactive Bladder Gel

Antares Pharma Inc. said Thursday the FDA has approved its topical gel for the treatment of overactive bladder. Overactive bladder (OAB) is a type of urinary incontinence and a form which, like urinary incontinence in general, can be associated with a number of factors, including BPH, prostatitis and prostate cancer and their treatments. Although millions… Continue Reading »


More about:

Toviaz Study Supports Treatment for Overactive Bladder

Pfizer Inc. (NYSE: PFE) today announced updated study results  for Toviaz (fesoterodine fumarate) for the effectiveness and safety for patients with Overactive Bladder/Incontinence including Nocturnal Urinary Urgency. Treatment for incontinence/OAB with Toviaz was found to be statistically significantly superior to placebo in reducing the number of urinary episodes overnight during sleep hours after 12 weeks… Continue Reading »


More about:

Overactive Bladder in Patients With Diabetes

According to a study published in the November issue of Urology, overactive bladder (OAB) is prevalent in patients with type 2 diabetes, with the prevalence higher in older patients and those with long-standing diabetes. Read more


More about:

Botox Approved For Urinary Incontinence

The Food and Drug Administration has approved Botox (onabotulinumtoxin A) for treatment of urinary incontinence that is the result of a neurologic condition, such as multiple sclerosis or a spinal cord injury, in adults who have not responded to or who cannot tolerate anticholinergic medications. Currently, the FDA approval does not extend to other causes… Continue Reading »


More about:

  • ADVERTISEMENT


  • ADVERTISEMENT